Audit: QRS - Safflower Oil for Health & Longevity

Audit conducted on 04/09/2026 02:12 using AI4L / Opus 5

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

Total = Passed + Failed + N/A
Pass Rate = Passed / (Passed + Failed) × 100
N/A items are excluded from the pass rate calculation

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Each populated span traces to ER text: 8 g/day and 15–30 mL/day to `Therapeutic Protocol`, the time-to-effect values to `Practical Considerations` and `Monitoring Protocol & Defining Success`, every biomarker row to the ER biomarker table, and the At-A-Glance to the ER `Conclusion`.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER hedge is dropped or replaced; the QRS carries no empty-state or certainty claim of its own.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications keep “avoid” force; the At-A-Glance scopes benefits to “people already unwell”, matching the ER `Conclusion` rather than broadening it.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gate items come only from `Key Interactions & Contraindications`; Benefits from `Expected Benefits`; Risks from `Potential Risks & Side Effects`. No `Benefit-Modifying Factors` or `Risk-Modifying Factors` content is surfaced.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, no citations, no expert names, no NCT identifiers and no brand names.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Phrasing mirrors the ER’s measured, evidence-first register (“people already unwell”, “one unexplained safety signal”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Targets and cadence are concrete and actionable while the harm signal is stated plainly.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Cells state findings and ranges rather than issuing instructions to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs in the QRS’s own voice; monitoring content is presented as a schedule of what moves when.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “should”, or “advised” appears in the populated spans.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns or imperatives directed at a reader.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to biomarker names and ER-sourced benefit labels.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are single clauses; marker “Why” cells are 3–8 words.
2.9	It DOES NOT address the reader directly	🟢	Confirmed across all populated spans; no “you” or “your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal functional ranges (ApoB < 80, HbA1c 4.8–5.4%) rather than conventional lab cut-offs signal that audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	The isocaloric substitution approach and a 12–16 week supplemental course assume that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Ten-marker monitoring panel including omega-3 index and ApoB is beyond general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The At-A-Glance flags that the benefit evidence comes from people already unwell and isolates the secondary-prevention harm signal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Clinical register is used throughout; the plainer wording in the At-A-Glance (“blood sugar”, “already unwell”, “cheap”) is taken from the ER `Conclusion` and is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (lines 446, 487, 529, 555, 566, 586, 609, 613–615, 739).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Extracted span-name sets match; the template’s `marker_#_` and `qualitative_item_#` row placeholders are expanded to `marker_1..10_` and `qualitative_item_1..5` as intended.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff of the non-variable lines shows the CSS block, `website="evidence_review"`, `website="audit"`, `website="full_review"` spans and the footer disclaimer are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped into the QRS is empty; the ER `Risks / High` case is governed by item 13.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	`action_1_label` “Standard supplemental dose”, `action_2_label` “Culinary substitution approach” and `action_3_label` “Single dose or split” reproduce the ER `Therapeutic Protocol` bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Benefit, risk and biomarker labels reproduce the ER’s `####` headings and the ER biomarker-table `Biomarker` column.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Codepoint scan of the `<body>` returns no emoji; the ER’s 🟩/🟥/🟨 and ⚠️ markers are all dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Eleven ER interaction bullets are compressed into eight gate items and the eight-item `Risk Mitigation Strategies` list is not carried over; per-section volume stays within the template budget.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14; the comment opens on line 2 immediately after `<!doctype html>` on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening `---` on line 3, closing `---` on line 13; the “QRS — Metadata” caption on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Wrapped in an HTML comment; no metadata value is repeated in the rendered header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only `duration: "00:03"` is quoted, and it contains a colon requiring it.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: `er_filename: safflower_oil_2026-0904-0002_Opus_ER.md`.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: `qrs_prompt_version: 26.7.02`, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: `qrs_creation_date: 2026-0904-0118`.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: `qrs_creator_ai_nickname: Opus`.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: `qrs_creator_ai_fullname: Opus 5`.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including `git_user` and `git_issue`; no stray whitespace or quoting.

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER `frontmatter` followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., `&` for `&`)	🟢	Line 22: “Safflower Oil for Health & Longevity - Quick Reference Sheet”, with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER `frontmatter`, with HTML entities encoded as needed (e.g., `&` for `&`)	🟢	Line 417: “Safflower Oil for Health & Longevity”, matching ER `canonical_topic`.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/04/2026”, the MM/DD/YYYY form of 2026-0904.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only title and subline; the ER’s `alternate_names` list is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER `Conclusion` section	🟢	Every clause maps to the ER `Conclusion` and it closes on the handling point (“rewards cool storage and gentle heat”).
7.2	[at_a_glance] is no longer than 60 words	🟢	Scripted count: exactly 60 words, at the limit.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Two forms / “almost everything … belongs to the first form” / “more reliably than any other common cooking fat” / “already unwell” / “one unexplained safety signal” / “cheap … rewards cool storage and gentle heat” all appear in the ER `Conclusion`.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “omega-6”, “cholesterol”, “blood sugar”, “waist size” are all everyday terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All four items come from that section’s “Populations who should avoid Safflower Oil” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Four ER avoid-population bullets map one-to-one onto four `<li>` items (lines 558–561).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is a separate `<li>` inside the `stop_items` span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s em-dash example list “— ragweed, chrysanthemum, marigold, echinacea —” and the uterine-contraction rationale are both stripped; no dashes remain in any item.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(daisy family)”, “within 90 days”, “(culinary oil unrestricted)”, “INR above 3.0” and “within 14 days” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section; the one threshold is written out as “an INR above 3.0”.
8.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four avoid-populations and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER `Key Interactions & Contraindications` section	🟢	All eight items derive from that section’s interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eleven ER interaction bullets are covered across eight `<li>` items (anticoagulants/antiplatelets/NSAIDs merged; seed oils merged with conjugated linoleic acid; statins merged with ketogenic diets); no contraindication is duplicated here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight separate `<li>` elements, lines 569–576.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s consequences and mitigating actions (INR recheck, four-week glucose recheck, two-hour separation from orlistat) are all stripped; no dashes remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(clopidogrel, ticagrelor, prasugrel)”, “(glipizide, glyburide, gliclazide)”, “(berberine, magnesium, aged garlic)” and “(weight-loss drug)” are kept; the antihypertensive parenthetical is retained in trimmed class form “(ACE inhibitors, calcium channel blockers)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s `Key Interactions & Contraindications` section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER lists eleven interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER `Protocol` section	🟢	All three cells derive from the ER `Therapeutic Protocol` bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER `Protocol` section	🟢	Dose (8 g/day), route of use (15–30 mL/day as isocaloric substitution) and dosing pattern (split) are the three decision-bearing bullets; the remaining bullets are modifiers rather than actions.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER `Protocol` section.	🟢	All nine fields carry ER-derived content (lines 450–482); “roughly 1.5 teaspoons”, “replacing butter, lard or coconut oil” and “reduces gastrointestinal complaints” all appear in the ER.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood lipids, glycaemic/inflammatory markers and blood pressure are the three outcome-bearing timelines in the ER `Practical Considerations` and `Monitoring Protocol & Defining Success` sections.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High (lipids), High (glycaemic control) then Medium (blood pressure), matching the ER benefit tiers.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“4–12 weeks”, “16 weeks” and “12 weeks” with their subs all trace to ER text (“respond within four to twelve weeks”, “only at sixteen weeks”, “Judging the protocol before four months is premature”).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the `Protocol Panel`	N/A	The ER provides an explicit “Time to effect” bullet, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER `Expected Benefits` section	🟢	All four tiers reproduce the ER `Expected Benefits` sub-headings at the matching tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present, lines 531–548.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare headings only; the ER’s magnitude figures (0.23–0.42 mmol/L, 0.64 percentage points, 2.4 cm) and mechanisms are all omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no benefits span needs hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER `Potential Risks & Side Effects` section	🟢	Medium, Low and Speculative items reproduce the ER sub-headings from that section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present, lines 588–603.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare headings only; the hazard ratios, confidence intervals and the ⚠️ Conflicted marker are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High”; line 588 is `<span data-qrs-var="risks_high" style="display: none"></span>` with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER `Monitoring` section	🟢	Rows and cadence derive from the ER `Monitoring Protocol & Defining Success` section.
14.2	All measurable/quantifiable biomarkers from the `Monitoring` section are listed	🟢	All ten ER biomarker-table rows appear as `marker_1` through `marker_10` with matching optimal ranges.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER `Monitoring` section. It is not left with placeholder text or empty.	🟢	Line 733 reproduces the ER’s baseline, 12-week, 16-week, 6–12-month and 4-week medication schedule.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER `Monitoring` section	🟢	All five items derive from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list.
15.2	All subjective/qualitative biomarkers from the `Monitoring` section are listed	🟢	All five ER qualitative markers are present as `qualitative_item_1` through `qualitative_item_5` (lines 742–754).

Issues 04/09/2026 02:12

Pass rate 100.00%. No issues found.

Issues 04/09/2026 02:02

1.1 — C-reactive protein mislabelled as glycaemic: The time_2 row (QRS lines 504–511) is labelled “Blood sugar and insulin sensitivity” but its sub reads “HbA1c and C-reactive protein”, presenting an inflammatory marker as a glycaemic readout; the ER groups the two only by their shared 16-week window (line 379) and the QRS’s own Monitoring row calls hs-CRP an “Inflammatory effect” marker (line 682).

Fixes 04/09/2026 02:02

1.1 — C-reactive protein mislabelled as glycaemic: Broadened time_2_label from “Blood sugar and insulin sensitivity” to “Blood sugar, insulin sensitivity and inflammation” so the sub’s “HbA1c and C-reactive protein” no longer presents an inflammatory marker as a glycaemic readout, matching the ER’s grouping of all three at sixteen weeks.

Issues 04/09/2026 01:58

1.3 — Hedge dropped from ALT rationale: [marker_8_why] at line 704 states “Fatty liver accompanies insulin resistance”, strengthening the ER’s hedged “Fatty liver often accompanies the insulin resistance being treated” (ER line 418) into a categorical claim.

Fixes 04/09/2026 01:58

1.3 — ALT rationale hedge restored: [marker_8_why] changed from “Fatty liver accompanies insulin resistance” to “Fatty liver often accompanies insulin resistance”, restoring the ER’s “often” hedge.

Issues 04/09/2026 01:54

2.5 / 2.6 / 2.9 — Imperative instruction in At-A-Glance: The At-A-Glance closes with “Cheap; store cool, heat gently” (line 437), a second-person imperative that advises the reader instead of presenting evidence; the ER states the same fact descriptively as “rewards cool storage and gentle heat” (ER line 456).
4.5 — Key Interactions gate overflows page budget: All 11 ER interaction bullets are carried as separate list items (lines 568–578) against 4 items in the paired Contraindications gate, pushing the gates grid and the overall sheet past one A4 page.

Fixes 04/09/2026 01:54

2.5 / 2.6 / 2.9 — Imperative removed from At-A-Glance: Replaced the second-person instruction “Cheap; store cool, heat gently” with the ER’s own descriptive phrasing, “Cheap; rewards cool storage and gentle heat”.
4.5 — Key Interactions condensed to page budget: Merged the 11 separate interaction list items into 8 by grouping the bleeding-risk drugs (anticoagulants, antiplatelets, aspirin/ibuprofen) and the omega-6 oils with conjugated linoleic acid, and trimmed the Orlistat gloss to “(weight-loss drug)”; all named drugs and interaction facts are retained.

Issues 04/09/2026 01:48

2.15 — Colloquial term for infarction: The Contraindications gate at line 558 uses the consumer-grade “heart attack” in the QRS’s own voice, where the ER at line 300 uses the clinical term “a myocardial infarction (heart attack) within 90 days”.

Fixes 04/09/2026 01:48

2.15 — Clinical term for infarction: Replaced the consumer-grade “heart attack” with the ER’s clinical term in the Contraindications gate, changing “Coronary heart disease (especially heart attack within 90 days)” to “Coronary heart disease (especially myocardial infarction within 90 days)”.

Issues 04/09/2026 01:42

1.3 — Hedge removed from qualitative marker: qualitative_item_1 (QRS line 744) states “which follows improved glucose handling”, strengthening the ER’s “which tends to follow improved glucose handling” (ER line 424).

Fixes 04/09/2026 01:42

1.3 — Hedge restored in qualitative marker: qualitative_item_1 changed from “which follows improved glucose handling” to “which tends to follow improved glucose handling”, matching the ER’s hedged wording.

Issues 04/09/2026 01:34

4.5 — Sheet overflows one A4 page: At the template’s print geometry the populated sheet measures roughly 1,800 px against a ~1,030 px A4 budget; the Monitoring “Why” cells (lines 649-768), the cadence sentence (lines 775-779), the 11 Key Interactions items (lines 583-596) and the five Qualitative items (lines 787-814) are carried over at near-ER length instead of being condensed to the per-section budget.

Fixes 04/09/2026 01:34

4.5 — Monitoring “Why” cells condensed: All ten marker_#_why cells were cut to short phrases (e.g. “The marker safflower oil moves most reliably” → “Moves most reliably”; “Captures the effect seen in metabolic syndrome and guards against additive hypotension” → “Metabolic-syndrome effect; hypotension guard”), collapsing most table rows from two rendered lines to one. All 10 biomarkers are retained per 14.2.
4.5 — Monitoring targets trimmed: marker_1_target shortened from “< 100 mg/dL; < 70 mg/dL with existing artery disease” to “< 100 mg/dL; < 70 with artery disease” so the target column no longer wraps.
4.5 — Cadence sentence tightened: monitoring_cadence rewritten as two short clauses (“Baseline; lipids and blood pressure at 12 weeks; …”) without dropping any of the ER’s four cadence facts.
4.5 — Qualitative items condensed: All five qualitative_item_# entries were shortened to single-line phrasing (e.g. “Energy stability through the late afternoon, which tends to follow improved glucose handling” → “Late-afternoon energy stability, which follows improved glucose handling”). All 5 markers are retained per 15.2.
4.5 — Decision-gate items shortened: The four Contraindications and the longest Key Interactions items were tightened (e.g. “Supplements with additive glucose or blood-pressure lowering (berberine, magnesium, aged garlic extract)” → “Glucose- or pressure-lowering supplements (berberine, magnesium, aged garlic)”), keeping every parenthetical qualifier and all 4 + 11 items per 8.5, 9.2 and 9.5.
4.5 — Time-to-effect subs trimmed: time_2_sub and time_3_sub were shortened to fit their protocol cells on two lines.

Note on residual scope: the sheet is materially shorter but still exceeds a single A4 page. Reducing it further would require dropping monitoring biomarkers, qualitative markers or interaction items, which items 14.2, 15.2 and 9.2 mandate be listed in full. The remaining overflow is a structural conflict between item 4.5 and those completeness items for this ER, not a condensation that was left undone.

Issues 04/09/2026 01:27

9.5 — Orlistat parenthetical dropped: Line 588 carries only “Orlistat”, dropping the ER’s parenthetical gloss “(over-the-counter weight-loss drug)” (ER line 283) entirely rather than trimming it, which item 9.5 forbids.

Fixes 04/09/2026 01:27

9.5 — Orlistat parenthetical restored: Changed the Key Interactions item from “Orlistat” to “Orlistat (over-the-counter weight-loss drug)”, restoring the ER’s parenthetical drug-class qualifier.